Literature DB >> 20181938

High regulatability favors genetic selection in SLC18A2, a vesicular monoamine transporter essential for life.

Zhicheng Lin1, Ying Zhao, Chee Yeun Chung, Yanhong Zhou, Nian Xiong, Charles E Glatt, Ole Isacson.   

Abstract

SLC18A2 encodes the vesicular monoamine transporter 2 protein that regulates neurotransmission and reduces cytosolic toxicity of monoamines. Deletion of this gene causes lethality in mice, and DNA sequence variation in this gene is associated with alcoholism and Parkinson's disease, among other disorders. The Caucasian SLC18A2 promoter has at least 20 haplotypes (A-T), with A representing two-thirds of 1460 chromosomes. It is not known why A is selected in the human lineage. To understand the selection, here we took a functional approach by investigating the regulations of 4 representative haplotypes (A, C, G, and T) by 17 agents. We show that 76.5% of the agents were able to regulate A but only 11.8-23.5% of them regulated the 3 other infrequent ones, observing a positive correlation between haplotype frequency and regulatability. Pathway and molecular analyses revealed five signaling hubs that regulate the four haplotypes differentially, probably through targeting the polymorphic core promoter region. These findings suggest that greater diversity of transcriptional regulations is the driving force for the haplotype selection in SLC18A2.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181938      PMCID: PMC2887259          DOI: 10.1096/fj.09-140368

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  35 in total

1.  Quantitative assessment of gene targeting in vitro and in vivo by the pancreatic transcription factor, Pdx1. Importance of chromatin structure in directing promoter binding.

Authors:  Swarup K Chakrabarti; Joshua C James; Raghavendra G Mirmira
Journal:  J Biol Chem       Date:  2002-02-01       Impact factor: 5.157

2.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

3.  Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size.

Authors:  E N Pothos; K E Larsen; D E Krantz; Y Liu; J W Haycock; W Setlik; M D Gershon; R H Edwards; D Sulzer
Journal:  J Neurosci       Date:  2000-10-01       Impact factor: 6.167

4.  Chronic clozapine, but not haloperidol, treatment affects rat brain vesicular monoamine transporter 2.

Authors:  Moshe Rehavi; Netta Roz; Abraham Weizman
Journal:  Eur Neuropsychopharmacol       Date:  2002-06       Impact factor: 4.600

5.  Effect of novel stressors on gene expression of tyrosine hydroxylase and monoamine transporters in brainstem noradrenergic neurons of long-term repeatedly immobilized rats.

Authors:  M Rusnák; R Kvetnanský; J Jeloková; M Palkovits
Journal:  Brain Res       Date:  2001-04-27       Impact factor: 3.252

6.  Transcriptional activation of the rat vesicular monoamine transporter 2 promoter in gastric epithelial cells: regulation by gastrin.

Authors:  F Watson; R S Kiernan; D G Deavall; A Varro; R Dimaline
Journal:  J Biol Chem       Date:  2000-12-11       Impact factor: 5.157

7.  In vivo measurement of the vesicular monoamine transporter in schizophrenia.

Authors:  S F Taylor; R A Koeppe; R Tandon; J K Zubieta; K A Frey
Journal:  Neuropsychopharmacology       Date:  2000-12       Impact factor: 7.853

8.  Increased platelet vesicular monoamine transporter density in adult schizophrenia patients.

Authors:  Michal Zucker; Avi Valevski; Abraham Weizman; Moshe Rehavi
Journal:  Eur Neuropsychopharmacol       Date:  2002-08       Impact factor: 4.600

9.  Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice.

Authors:  F Scott Hall; I Sora; G R Uhl
Journal:  Neuropsychopharmacology       Date:  2002-09-20       Impact factor: 7.853

10.  The proapoptotic dp5 gene is a direct target of the MLK-JNK-c-Jun pathway in sympathetic neurons.

Authors:  Emily Towers; Jonathan Gilley; Rebecca Randall; Rosie Hughes; Mark Kristiansen; Jonathan Ham
Journal:  Nucleic Acids Res       Date:  2009-03-20       Impact factor: 16.971

View more
  11 in total

1.  Identification of an intronic cis-acting element in the human dopamine transporter gene.

Authors:  Ying Zhao; Yanhong Zhou; Nian Xiong; Zhicheng Lin
Journal:  Mol Biol Rep       Date:  2011-12-13       Impact factor: 2.316

2.  Human dopamine transporter gene: differential regulation of 18-kb haplotypes.

Authors:  Ying Zhao; Nian Xiong; Yang Liu; Yanhong Zhou; Nuomin Li; Hong Qing; Zhicheng Lin
Journal:  Pharmacogenomics       Date:  2013-09       Impact factor: 2.533

3.  Edaravone prevents neurotoxicity of mutant L166P DJ-1 in Parkinson's disease.

Authors:  Bing Li; Dawei Yu; Zhiying Xu
Journal:  J Mol Neurosci       Date:  2013-05-10       Impact factor: 3.444

4.  hVMAT2: A Target of Individualized Medication for Parkinson's Disease.

Authors:  Nian Xiong; Nuomin Li; Eden Martin; Jinlong Yu; Jie Li; Jing Liu; David Yue-Wei Lee; Ole Isacson; Jeffery Vance; Hong Qing; Tao Wang; Zhicheng Lin
Journal:  Neurotherapeutics       Date:  2016-07       Impact factor: 7.620

Review 5.  Vesicular integrity in Parkinson's disease.

Authors:  Shawn P Alter; Gina M Lenzi; Alison I Bernstein; Gary W Miller
Journal:  Curr Neurol Neurosci Rep       Date:  2013-07       Impact factor: 5.081

6.  Computational dissection of human episodic memory reveals mental process-specific genetic profiles.

Authors:  Gediminas Luksys; Matthias Fastenrath; David Coynel; Virginie Freytag; Leo Gschwind; Angela Heck; Frank Jessen; Wolfgang Maier; Annette Milnik; Steffi G Riedel-Heller; Martin Scherer; Klara Spalek; Christian Vogler; Michael Wagner; Steffen Wolfsgruber; Andreas Papassotiropoulos; Dominique J-F de Quervain
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

7.  Genetic Variation in the Vesicular Monoamine Transporter: Preliminary Associations With Cognitive Outcomes After Severe Traumatic Brain Injury.

Authors:  Steven M Markos; Michelle D Failla; Anne C Ritter; C Edward Dixon; Yvette P Conley; Joseph H Ricker; Patricia M Arenth; Shannon B Juengst; Amy K Wagner
Journal:  J Head Trauma Rehabil       Date:  2017 Mar/Apr       Impact factor: 2.710

8.  Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease.

Authors:  Nian Xiong; Jing Xiong; Ghanshyam Khare; Chunnuan Chen; Jinsha Huang; Ying Zhao; Zhentao Zhang; Xian Qiao; Yuan Feng; Harrish Reesaul; Yongxue Zhang; Shenggang Sun; Zhicheng Lin; Tao Wang
Journal:  PLoS One       Date:  2011-06-03       Impact factor: 3.240

9.  Genome-wide differential expression of synaptic long noncoding RNAs in autism spectrum disorder.

Authors:  Y Wang; X Zhao; W Ju; M Flory; J Zhong; S Jiang; P Wang; X Dong; X Tao; Q Chen; C Shen; M Zhong; Y Yu; W T Brown; N Zhong
Journal:  Transl Psychiatry       Date:  2015-10-20       Impact factor: 6.222

10.  Epistatic evidence for gender-dependant slow neurotransmission signalling in substance use disorders: PPP1R12B versus PPP1R1B.

Authors:  Kefu Liu; Juan Zhao; Chunnuan Chen; Jie Xu; Richard L Bell; Frank S Hall; George F Koob; Nora D Volkow; Hong Qing; Zhicheng Lin
Journal:  EBioMedicine       Date:  2020-10-21       Impact factor: 8.143

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.